The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light from ANVISA.
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos in Brazil (Yahoo Finance)
Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, announces the signature of a partnership with Innovation Solutions Pharma, a company specializing in support for clinical development and drug registration operations in South America, with a view to accelerate market access for Sarconeos (BIO101) in Brazil. As part of this partnership, Innovative Solutions Pharma will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022.
Anvisa approves bronchiolitis vaccine registration (ANVISA Website, in Portuguese)
The National Health Surveillance Agency (ANVISA) approved the registration of a vaccine indicated for the prevention of lower respiratory tract disease caused by the respiratory syncytial virus (RSV). This is the main virus that causes bronchiolitis. The approved immunizer is registered as Arexvy, produced by the company GSK.
Merck’s 100 years in Brazil (Guia de Farmacia, in Portuguese)
Throughout the year, executive José Arnaud Coelho, president of Merck Brasil, dedicated part of his agenda to commemorating 100 years of business in the country. A subsidiary is the majority of the group’s operations worldwide, with 33 percent of sales in the healthcare division (medication) in Latin America and a growing performance.
Eurofarma Ventures to invest up to USD$100 million in biotechs (Contxto)
Eurofarma, a Brazilian pharmaceutical company, announced the creation of a corporate venture capital fund aimed at supporting innovative companies in the field of biotechnology. It plans to invest up to USD$100 million in startups, known as biotechs, in the early stages of research and development of medicines.
Named Eurofarma Ventures, this corporate fund was established to strengthen the company’s presence in the field of innovation, aiming to collaborate with startups adopting disruptive approaches at the frontier of science and pharmaceutical research.
Radar Fit, a Brazilian healthtech company, has secured a USD $1 million investment from WE Ventures (Contxto)
Radar Fit, the innovative health and wellness application founded in 2018, has announced a USD $1 million investment from WE Ventures, a venture capital (VC) fund that is part of Women Entrepreneurship, an initiative created by Microsoft Participações in partnership with Sebrae Nacional, M8 Partners, and in collaboration with Bertha Capital. This investment, made in conjunction with the recently launched Hiker Ventures, adds up to a total of R$ 5 million aimed at driving the expansion strategy and gaining market share in Brazil’s healthcare technology sector.
Brazilian Researchers Develop Vaccine to Fight Cocaine Addiction (Voanews)
Researchers in Brazil have developed a vaccine designed to fight addiction to cocaine and its potent derivative crack — by preventing addicts from feeling the effects of the drugs and helping them stay on track for recovery. The drug, known as Calixcoca, was developed by a team at Brazil’s Federal University of Minas Gerais. Preliminary tests on animals were positive and the drug is set to move to human trials.
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA (PR Newswire)
Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority of Brazil, ANVISA.
Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and Chang-Jae Lee, proudly announced that their Osong factory passed the Brazilian Good Manufacturing Practice (GMP) inspection with a flawless “Zero” Observation in terms of compliance. This success in the rigorous GMP inspection underscores the Osong plant’s commitment to the highest quality standards and the excellence of its smart manufacturing practices.
